Lung Density Analysis

The Imbio CT Lung Density Analysis Software is a post-processing tool that analyzes DICOM CT thoracic datasets to provide quantitative metrics for pulmonary tissue, including 3D segmentation, volumetric analysis, and density evaluations. It employs image processing algorithms for segmentation, registration, and thresholding to support physicians in diagnosing, documenting, and following up on lung abnormalities by generating reproducible CT values and reports.

The Imbio CT Lung Density Analysis Software is a standalone, post-processing application designed to analyze CT thoracic datasets of the human lungs. Its primary purpose is to provide reproducible CT values and quantitative support for physicians in the diagnosis, documentation, and follow-up examinations of pulmonary tissue images, including abnormalities. The software achieves this through functionalities such as 3D segmentation and isolation of pulmonary sub-compartments, volumetric analysis, density evaluations, image registration (including automated registration of inspiration/expiration image pairs), thresholding, classification, and the generation of comprehensive reports. It processes DICOM images and is intended for prescription use, functioning via a command-line interface. The software operates by importing DICOM files previously generated by CT data acquisition equipment; it does not directly interface with scanners. It employs a suite of image processing algorithms, implemented as elemental C++ functions and separate modules, to perform its analytical tasks. The output consists of DICOM files and reports that visually represent the segmented lungs, often with color-coding to indicate different density characteristics based on thresholding and classification rules. Non-clinical testing was performed to verify its core functionalities, including image processing completion, segmentation, and thresholding. Software quality was managed through a defined development lifecycle, risk assessment, configuration management, and issue tracking.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the software's automated registration of inspiration/expiration image pairs compare in accuracy and efficiency to manual methods or other automated tools?; What is the validated range of CT scanner models, acquisition parameters (e.g., slice thickness, reconstruction kernels), and contrast levels for which the software maintains its stated accuracy in density and volumetric measurements?; Can the software differentiate and quantify various patterns of lung density changes, such as those seen in emphysema versus ground-glass opacities, and what is the basis for this differentiation?; What are the specific thresholding values or ranges (e.g., Hounsfield Units) used by the software for classifying different lung tissue densities, and is there a mechanism for user adjustment or site-specific calibration?; How does the software account for potential confounders like respiratory motion artifacts or partial volume effects, especially in the segmentation and density evaluation of peripheral lung regions or small abnormalities?